Alternate Pre-med in Anti-Cluster of Differentiation 20 (CD20) Pilot Project
ConditionMultiple Sclerosis
Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Miami
About this trial
The purpose of this study is to assess and compare how well multiple sclerosis (MS) patients tolerate cetirizine versus diphenhydramine as a pre-medication before receiving anti-CD20 infusion therapy of ocrelizumab, ublituximab or rituximab. The study will also compare the safety of cetirizine versus diphenhydramine as a pre-medication for preventing infusion reactions in MS patients receiving anti-CD20 infusion therapy.
Eligibility criteria
Qualifiers
Ages ≥18 years
Able to read and speak in English or Spanish
Able to and willing to give informed consent
Diagnosis of Multiple Sclerosis (MS)
Disqualifiers
Adults unable or unwilling to consent
Patients younger than 18 years of age
Pregnant women
Known hypersensitivity to cetirizine or any of its ingredients or hydroxyzine
Trial design
Treatments tested in this trial
- Cetirizine
- Diphenhydramine
Treatment groups
60 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov